Stock Events

Stock Events

Pacific Biosciences of California 

$1.58
379
+$0.03+1.94% Tuesday 20:00

Statistics

Day High
1.58
Day Low
1.5
52W High
2.67
52W Low
0.91
Volume
5,773,324
Avg. Volume
-
Mkt Cap
477.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.44
-0.96
-0.47
0.01
Expected EPS
-0.141667
Actual EPS
N/A

Financials

-341.47%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
320.01MRevenue
-1.09BNet Income

Analyst Ratings

1.67Average Price Target
The highest estimate is 2.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
33%
Sell
33%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PACB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.63B
Illumina offers sequencing and array-based solutions for genetic and genomic analysis, directly competing in the DNA sequencing market with PACB.
Bionano Genomics
BNGO
Mkt Cap13.09M
Bionano Genomics provides optical genome mapping solutions, which compete with PACB's long-read sequencing technologies.
Thermo Fisher Scientific
TMO
Mkt Cap174.37B
Thermo Fisher Scientific offers a range of sequencing and genetic analysis products, competing in the broader genomics space with PACB.
Qiagen NV
QGEN
Mkt Cap7.06B
Qiagen offers sample to insight solutions including sequencing technologies that compete with PACB's offerings.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is involved in CRISPR gene editing, a field that relies on accurate DNA sequencing, where PACB's technologies are used.
Editas Medicine
EDIT
Mkt Cap283.93M
Editas Medicine operates in the genome editing space, competing indirectly by relying on sequencing technologies similar to those offered by PACB for its gene editing projects.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is engaged in gene-based medicine, depending on sequencing technologies where PACB's long-read capabilities are beneficial.
Agenus
AGEN
Mkt Cap147.45M
Agenus is involved in immuno-oncology, a field that increasingly relies on genomic sequencing for personalized medicine, indirectly competing with PACB.
Guardant Health
GH
Mkt Cap11.61B
Guardant Health focuses on liquid biopsies and cancer diagnostics, using sequencing technologies that compete with PACB's offerings in the genomic analysis market.

About

There is no Profile data available for P09.SG.
Show more...
CEO
Mr. Christian O. Henry M.B.A.
Employees
575
Country
United States
ISIN
US69404D1081

Listings

MX
MX
PACB.MX
MU
DE
P09.MU
STU
DE
P09.STU
F
DE
P09.F

0 Comments

Share your thoughts

FAQ

What is Pacific Biosciences of California stock price today?▼
The current price of PACB is $1.58 USD — it has increased by +1.94% in the past 24 hours. Watch Pacific Biosciences of California stock price performance more closely on the chart.
What is Pacific Biosciences of California stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pacific Biosciences of California stocks are traded under the ticker PACB.
Is Pacific Biosciences of California stock price growing?▼
PACB stock has risen by +7.48% compared to the previous week, the month change is a +11.27% rise, over the last year Pacific Biosciences of California has showed a +43.64% increase.
What is Pacific Biosciences of California market cap?▼
Today Pacific Biosciences of California has the market capitalization of 477.16M
When is the next Pacific Biosciences of California earnings date?▼
Pacific Biosciences of California is going to release the next earnings report on May 07, 2026.
What were Pacific Biosciences of California earnings last quarter?▼
PACB earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.14 USD resulting in a +9.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pacific Biosciences of California revenue for the last year?▼
Pacific Biosciences of California revenue for the last year amounts to 320.01M USD.
What is Pacific Biosciences of California net income for the last year?▼
PACB net income for the last year is -1.09B USD.
How many employees does Pacific Biosciences of California have?▼
As of May 06, 2026, the company has 575 employees.
In which sector is Pacific Biosciences of California located?▼
Pacific Biosciences of California operates in the Health & Wellness sector.
When did Pacific Biosciences of California complete a stock split?▼
Pacific Biosciences of California has not had any recent stock splits.
Where is Pacific Biosciences of California headquartered?▼
Pacific Biosciences of California is headquartered in Menlo Park, United States.